DRAP Publishes Guidance on Registration Pathways for Pharmaceutical and Biological Drugs
The Drug Regulatory Authority of Pakistan (DRAP) has released a guidance document describing the registration pathways available for pharmaceutical and biological drugs for human use.
The document sets out the routes through which medicines can be registered in Pakistan and is aimed mainly at applicants, manufacturers and importers. The full guidance is available as a download on the DRAP website.
Key points
- Issued by DRAP on 17 September 2026.
- Covers registration pathways for both pharmaceutical and biological drugs for human use.
- Relevant to manufacturers, importers and regulatory affairs teams.
- The complete document can be downloaded from the DRAP announcement.
What it means for you
Pharmacists working in regulatory affairs, hospital procurement or industry should read the full guidance, since registration routes determine how quickly new medicines reach the Pakistani market.
Guidance on the Registration Pathways for Pharmaceutical and Biological Drugs for Human Use
Summarised automatically from the official announcement. For educational purposes only — check the original source before making clinical decisions.